Magnetom essenza 1.5t

Animals were inspected twice daily for the first postoperative week and once per day for the rest of the implantation period. Physical and orthopedic examinations were performed every day, with the observer unaware of the treatment group. Postoperative lameness was graded as 0 = no lameness, grade 1 = slight intermittent weight‐bearing lameness, grade 2 = slight to moderate persistent weight‐bearing lameness, grade 3 = severe persistent weight‐bearing lameness, and grade 4 = persistent non–weight‐bearing lameness. Twenty weeks after implantation, radiographic and MRI examinations of the stifle were performed with the animals in dorsal recumbency and under general anesthesia. T1 3D Vibe, T1 TSE, and T2 TSE sequences (Magnetom Essenza 1.5T; Siemens, Munich, Germany) were used for MRI examination. Animals were then humanely killed with an IV overdose of pentobarbital, and the distal femoral ends were immediately dissected for macroscopic evaluation.

All CT-3D were performed in a 64- or 128-channel scanner, Siemens Somatom Sensation or Siemens Somatom Definition AS, respectively, (Siemens AG, Munich, Germany) in supine position and with limbs in neutral rotation.
Magnetic resonance imaging and arthro-MRI scans (Magnetom Essenza 1.5 T - Siemens Healthcare, Erlangen, Germany) were performed in supine position, with the shoulder in neutral rotation, using T2-weighted sequences with or without fat suppression (TR/TE 2280/42, field of view 160 × 100 mm, matrix 384 × 70, 3-mm thickness) in postprocessed axial, sagittal, and coronal views (Kodak Carestream PACS, Belo Horizonte, Minas Gerais, Brazil).
Glenoid track, HSI, GBL calculations, and on-track/off-track classifications were performed in 3D-CT scans as described by Di Giacomo et al.
3 (link)
(
Figure 1Aand
1B. The same calculations were performed in MRI/arthro-MRI scans as reported by Guyftpoulos et al.
4 (link)
(
Figure 2Aand
2B). Glenoid track was determined using the formula GT = 0.83D – d.
Data was analyzed with the IBM SPSS software 23.0. (IBM Corp., Armonk, NY, USA). The level of significance was 5% for the entire study. This study was approved by the institutional research ethics committee.